Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telisotuzumab Adizutecan + Osimertinib in 1L EGFR-Mutated Non-Squamous NSCLC
NCT07005102Phase 3Recruiting
- Sponsor
- AbbVie Inc.
- Start
- Aug 2025
- Primary completion
- Nov 2036
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs), Engineered Antibody Formats
- Countries
- 13
01
Overview
A Phase 3 trial of telisotuzumab adizutecan in non-small cell lung cancer (NSCLC), sponsored by AbbVie Inc.. Started Aug 2025; status: recruiting.
02
Drugs
telisotuzumab adizutecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT07005102.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07005102.